Movement Alert｜Hengrui Medicine Rises 3.73% in Regular Trading, First Self-Developed Innovative Drug Marketing Application Accepted by EMA

Market Focus06-23

On June 23, Hengrui Medicine rose 3.73% in regular trading, trading at 57.45 HKD/share, with turnover of approximately 42.72 million HKD.

On the news front, the company announced on June 22 that the European Medicines Agency (EMA) has formally accepted the marketing authorization application for its rilvegostomab tablets. This marks the first self-developed innovative drug by Hengrui to be submitted for marketing approval in the European Union. The drug is indicated for combination with androgen deprivation therapy (ADT) for the treatment of adult male patients with high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC).

The positive momentum is further supported by multiple recent catalysts, including Schroders increasing its stake to 5.11% on June 12, the NMPA approval of a new indication for its CDK4/6 inhibitor dalpiciclib isethionate tablets, and clinical trial approvals for HRS-7525 tablets and SHR-6914 injection. Additionally, the company confirmed it is continuing its A-share buyback program with a total fund of no less than 10 billion RMB and no more than 20 billion RMB, signaling management confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196099833?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196099833","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hengrui Medicine Rises 3.73% in Regular Trading, First Self-Developed Innovative Drug Marketing Application Accepted by EMA","media":"Market Focus","content":"<p><p>On June 23, Hengrui Medicine rose 3.73% in regular trading, trading at 57.45 HKD/share, with turnover of approximately 42.72 million HKD.</p><p>On the news front, the company announced on June 22 that the European Medicines Agency (EMA) has formally accepted the marketing authorization application for its rilvegostomab tablets. This marks the first self-developed innovative drug by Hengrui to be submitted for marketing approval in the European Union. The drug is indicated for combination with androgen deprivation therapy (ADT) for the treatment of adult male patients with high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC).</p><p>The positive momentum is further supported by multiple recent catalysts, including Schroders increasing its stake to 5.11% on June 12, the NMPA approval of a new indication for its CDK4/6 inhibitor dalpiciclib isethionate tablets, and clinical trial approvals for HRS-7525 tablets and SHR-6914 injection. Additionally, the company confirmed it is continuing its A-share buyback program with a total fund of no less than 10 billion RMB and no more than 20 billion RMB, signaling management confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hengrui Medicine Rises 3.73% in Regular Trading, First Self-Developed Innovative Drug Marketing Application Accepted by EMA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hengrui Medicine Rises 3.73% in Regular Trading, First Self-Developed Innovative Drug Marketing Application Accepted by EMA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, Hengrui Medicine rose 3.73% in regular trading, trading at 57.45 HKD/share, with turnover of approximately 42.72 million HKD.</p><p>On the news front, the company announced on June 22 that the European Medicines Agency (EMA) has formally accepted the marketing authorization application for its rilvegostomab tablets. This marks the first self-developed innovative drug by Hengrui to be submitted for marketing approval in the European Union. The drug is indicated for combination with androgen deprivation therapy (ADT) for the treatment of adult male patients with high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC).</p><p>The positive momentum is further supported by multiple recent catalysts, including Schroders increasing its stake to 5.11% on June 12, the NMPA approval of a new indication for its CDK4/6 inhibitor dalpiciclib isethionate tablets, and clinical trial approvals for HRS-7525 tablets and SHR-6914 injection. Additionally, the company confirmed it is continuing its A-share buyback program with a total fund of no less than 10 billion RMB and no more than 20 billion RMB, signaling management confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1196099833","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196099833","pubTimestamp":1782178654,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, Hengrui Medicine rose 3.73% in regular trading, trading at 57.45 HKD/share, with turnover of approximately 42.72 million HKD.On the news front, the company announced on June 22 that the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"动静快讯|恒瑞医药常规交易涨3.73%首个自研创新药上市申请获EMA受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On June 23, Hengrui Medicine rose 3.73% in regular trading, trading at 57.45 HKD/share, with turnover of approximately 42.72 million HKD.On the news front, the company announced on June 22 that the European Medicines Agency (EMA) has formally accepted the marketing authorization application for its rilvegostomab tablets. This marks the first self-developed innovative drug by Hengrui to be submitted for marketing approval in the European Union. The drug is indicated for combination with androgen deprivation therapy (ADT) for the treatment of adult male patients with high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC).The positive momentum is further supported by multiple recent catalysts, including Schroders increasing its stake to 5.11% on June 12, the NMPA approval of a new indication for its CDK4/6 inhibitor dalpiciclib isethionate tablets, and clinical trial approvals for HRS-7525 tablets and SHR-6914 injection. Additionally, the company confirmed it is continuing its A-share buyback program with a total fund of no less than 10 billion RMB and no more than 20 billion RMB, signaling management confidence.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196099833","isCrawlerRequest":true}